The global CNS biomarker market was estimated at $1.3 billion in 2009 and is expected to reach close to $3.2 billion by 2015, with a compound annual growth rate (CAGR) of 17.1% from 2010 to 2015.
The CNS molecular diagnostic market will see the largest growth, with a compound annual growth rate (CAGR) of 172.3% from 2010 to 2015 due to the number of diagnostic tests that are in the pipeline. This sector is valued at $2 million in 2010 and is expected to be worth $302 million in 2015.
The growth rate for the CNS biomarker market for drug development will increase as more validated biomarkers become available for patient segmentation and assessment of efficacy for clinical trials. This sector is worth an estimated $162 million in 2010 and is expected to reach $355 million in 2015, a 17% compound annual growth rate (CAGR).
Biomarkers are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response. They have played, and will continue to play, an important role in drug R&D and in diagnostics. They are important tools for understanding disease mechanism, developing more effective treatments, and improving the quality of patient care. The discovery of biomarkers for CNS disorders has gained considerable interest within the pharmaceutical industry due to the many unmet needs in current treatments and diagnostics.
Here we examine the role of CNS biomarkers in early discovery, in drug development, and for future diagnostics. We assess the global CNS biomarker market and make forecasts from 2010 to 2015. We further segment the market by application, technology (genomics, proteomics, and molecular imaging), and region. We discuss the different disease segments, describing gaps in treatment and limitations of current methods of diagnosis. The process of developing biomarkers from discovery to commercialization is discussed along with the forces in the industry that play an integral role, such as payers, providers, and suppliers. We also address the growth drivers and growth inhibitors that can affect CNS biomarker adoption.
STUDY GOALS AND OBJECTIVES
To assess the various technologies used for CNS biomarker discovery and future diagnostics.
To understand the process of CNS biomarker development from discovery to commercialization and the path towards adoption.
To examine the regulatory landscape and government’s role.
To examine the unmet needs in diagnosis and treatment of various CNS disorders.
To determine current and future CNS biomarker markets.
REASONS FOR DOING THE STUDY
This study was conducted to determine the current and future global demand for CNS biomarkers, taking into account various competitive forces, growth drivers, and growth barriers that are at play.
SCOPE OF REPORT
This market research report:
Reviews technologies used to identify biomarkers for drug discovery, drug development, and diagnostic purposes specifically within the central nervous system (CNS) market
Analyzes global market trends, with data for 2009, estimates for 2010, and projections of compound annual growth rates through 2015
Evaluates technologies such as genomics, proteomics, and imaging, and weighs their advantages and disadvantages
Discusses CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others
Presents comprehensive company profiles and patent analyses.
The study examines the current and future role of CNS biomarkers and their effect on various industries. Biotechnology companies, pharmaceutical companies, research institutions, physicians, hospitals, and manufacturers of genomic/proteomic supplies and technologies can all potentially benefit from strategic use of the market data and analysis contained in this report.
BCC conducted primary and secondary market research to obtain market data for analysis and forecast projections. Interviews were conducted with experts in the industry, and data and information were compiled from government and public data sources, press releases, trade journals, publications, and selected databases.
Munish Das is founder of BioEvolution LLC, a business research and consulting firm focused on healthcare. He has worked in the biotech and pharmaceutical industry for the past 10 years. He holds a master’s degree in biotechnology and business administration.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
Examine BCC’s complete catalog of Market Research Reports and place direct orders
Subscribe to any of BCC’s many industry newsletters
Read announcements of recently published reports and newly launched newsletters
Register for BCC’s well-known conferences
Request additional information on any BCC product
Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Need a custom data table, graph or complete report? Tell us more.
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth opportunities, market sizing, technologies, applications, supply chains and companies with the singular goal of helping you make informed business decisions, free of noise and hype.
Thank you for your interest in BCC Research. You will be added to our mailing list.